Vuélvete ilimitado con Magzter GOLD

Vuélvete ilimitado con Magzter GOLD

Obtenga acceso ilimitado a más de 9000 revistas, periódicos e historias Premium por solo

$149.99
 
$74.99/Año

Intentar ORO - Gratis

Momentum funds outpace others. Will stellar run last?

Mint Mumbai

|

September 19, 2025

Since the launch of first momentum fund in 2021, their number has climbed to 40

- Srushti Vaidya

Momentum funds outpace others. Will stellar run last?

They were late to the party—but they’re catching up fast. Momentum funds, barely four years old in India, have already overtaken older, more established factor strategies.

Since the launch of the first momentum fund in 2021, the number of momentum-based funds has climbed to 40, surpassing value investing (38 funds) and quality investing (32 funds), which have existed since 1994, according to Value Research.

As of September, value funds stood at 38, while quality funds were at 32, according to data from Value Research.

The reason: a strong run of outperformance by momentum in recent years, which has prompted asset management companies to roll out new momentum funds to capture surging investor interest.

The benchmark BSE 500 Momentum 50 Total Return Index has delivered 34.24% compound annual growth rate (CAGR) returns over the past five years since 2020—beating the BSE 500 Quality 50 Total Return Index and the BSE 500 Total Return Index for value, which returned 23.28% and 20.26% CAGR, respectively. These are point-to-point returns.

MÁS HISTORIAS DE Mint Mumbai

Mint Mumbai

Mint Mumbai

Gen Alpha will make new rules for their workplace

Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’

time to read

3 mins

December 01, 2025

Mint Mumbai

EC extends electoral roll revision by a week to II Dec; final list on 14 Feb

The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.

time to read

2 mins

December 01, 2025

Mint Mumbai

THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS

These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.

time to read

3 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

Green hydrogen: Fast fashion could help bump up demand

A boom in its use for clean synthetic inputs might make a difference

time to read

3 mins

December 01, 2025

Mint Mumbai

Let's be a bit more selective in using the word 'reforms'

Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.

time to read

3 mins

December 01, 2025

Mint Mumbai

As mid-cap alpha shrinks, should you consider passive strategies?

Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey

time to read

4 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

With $2.2 bn fund, ChrysCap has appetite for riskier bets

MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing

time to read

3 mins

December 01, 2025

Mint Mumbai

GDP growth of 8% plus: How to sustain this pace

Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships

time to read

2 mins

December 01, 2025

Mint Mumbai

INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES

Detection tools today are not universal or consistent across languages

time to read

5 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

APIs to innovation: Bulk drug makers ramp up CDMO bets

Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.

time to read

2 mins

December 01, 2025

Listen

Translate

Share

-
+

Change font size